No

Local Anesthetic

Infiltration anesthesia and peripheral and epidural anesthesia

C

Known hypersensitivity to chloroprocaine, or other ester type anesthetics; myasthenia gravis; concurrent use of bupivacaine; do not use for subarachnoid administration

Use with caution in patients with cardiac disease, renal disease, and hyperthyroidism; convulsions and cardiac arrest have been reported presumably due to intravascular injection

<1%: Myocardial depression, hypotension, bradycardia, cardiovascular collapse, edema, anxiety, restlessness, disorientation, confusion, seizures, drowsiness, unconsciousness, chills, urticaria, nausea, vomiting, transient stinging or burning at injection site, tremor, blurred vision, tinnitus, respiratory arrest, anaphylactoid reactions, shivering

Treatment is primarily symptomatic and supportive. Termination of anesthesia by pneumatic tourniquet inflation should be attempted when the agent is administered by infiltration or regional injection. Hypotension responds to I.V. fluids and Trendelenburg positioning. Other symptoms (seizures, bradyarrhythmias, metabolic acidosis, methemoglobinemia) respond to conventional treatments.

PABA (from ester-type anesthetics) may inhibit sulfonamides

Chloroprocaine HCl is benzoic acid, 4-amino-2-chloro-2-(diethylamino) ethyl ester monohydrochloride. Chloroprocaine is an ester-type local anesthetic, which stabilizes the neuronal membranes and prevents initiation and transmission of nerve impulses thereby affecting local anesthetic actions. Local anesthetics including chloroprocaine, reversibly prevent generation and conduction of electrical impulses in neurons by decreasing the transient increase in permeability to sodium. The differential sensitivity generally depends on the size of the fiber; small fibers are more sensitive than larger fibers and require a longer period for recovery. Sensory pain fibers are usually blocked first, followed by fibers that transmit sensations of temperature, touch, and deep pressure. High concentrations block sympathetic somatic sensory and somatic motor fibers. The spread of anesthesia depends upon the distribution of the solution. This is primarily dependent on the volume of drug injected.

Onset of action: 6-12 minutes

Duration: 30-60 minutes

Dosage varies with anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, depth of anesthesia required, degree of muscle relaxation required, and duration of anesthesia; range: 1.5-25 mL of 2% to 3% solution; single adult dose should not exceed 800 mg

Infiltration, peripheral and central nerve block, including caudal and epidural block: 2% to 3%, without preservatives

No information available to require special precautions

No effects or complications reported

This medication is given to reduce sensation in the injected area. You will experience decreased sensation to pain, heat, or cold in the area and/or decreased muscle strength (depending on area of application) until the effects wear off; use necessary caution to reduce incidence of possible injury until full sensation returns. Immediately report chest pain or palpitations; increased restlessness, confusion, anxiety, or dizziness; difficulty breathing; chills, shivering, or tremors; ringing in ears; or changes in vision. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Consult prescriber if breast-feeding.

Must have resuscitative equipment available

Injection, as hydrochloride:

With preservative (Nesacaine®): 1% (30 mL); 2% (30 mL)

Freeman DW and Arnold NI, "Paracervical Block With Low Doses of Chloroprocaine: Fetal and Maternal Effects," JAMA, 1975, 231(1):56-7.